MARKET

XCUR

XCUR

EXICURE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.480
+0.080
+3.33%
Opening 12:09 07/02 EDT
OPEN
2.480
PREV CLOSE
2.400
HIGH
2.500
LOW
2.400
VOLUME
43.63K
TURNOVER
--
52 WEEK HIGH
3.840
52 WEEK LOW
0.9573
MARKET CAP
216.13M
P/E (TTM)
-7.6520
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XCUR stock price target is 10.00 with a high estimate of 18.00 and a low estimate of 5.00.

EPS

XCUR News

More
Exicure, Inc. Added to Russell 2000® Index
Business Wire · 3d ago
Exicure Presents Cavrotolimod (AST-008) Clinical Data at AACR 2020 Virtual Meeting
Exicure is presenting updated pharmacodynamic and safety data at the American Association of Cancer Research (AACR) Virtual Annual Meeting II.
Business Wire · 06/22 11:00
Exicure, Inc. to Present at the 2020 BMO Prescription for Success Healthcare Conference
Business Wire · 06/18 12:00
Dosing underway in Exicure's mid-stage merkel cell carcinoma trial of AST-008
Seeking Alpha - Article · 06/16 12:24
Exicure Announces First Patient Dosed in Phase 2 Merkel Cell Carcinoma Trial of Cavrotolimod (AST-008)
Business Wire · 06/16 12:00
Exicure Announces First Patient Dosed In Phase 2 Merkel Cell Carcinoma Trial Of Cavrotolimod (AST-008)
Benzinga · 06/16 11:05
Week 25 MDA Breakout Forecast: Short-Term Stocks To Give You An Edge
Seeking Alpha - Article · 06/14 06:23
3 Strong Buy Penny Stocks That Could See Outsized Returns
TipRanks · 06/04 14:46

Industry

Biotechnology & Medical Research
+1.06%
Pharmaceuticals & Medical Research
+0.70%

Hot Stocks

Symbol
Price
%Change

About XCUR

Exicure, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for immuno-oncology, genetic disorders and other indications based on its Spherical Nucleic Acid (SNA) technology. SNA is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Its pipeline includes AST-008, XCUR-FXN and XCUR17. AST-008 product is a toll-like receptor 9 agonist designed to activate the innate immune system and induce a potent anti-cancer immune response, especially in combination with checkpoint inhibitors. XCUR-FXN is a preclinical program for the treatment of Friedreich’s ataxia (FA). XCUR17 is being developed for inflammatory disorders, netherton syndrome and hair loss disorders. XCUR17 is an SNA that targets the mRNA that encodes interleukin 17 receptor alpha (IL-17RA).
More

Webull offers kinds of Exicure Inc stock information, including NASDAQ:XCUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XCUR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XCUR stock methods without spending real money on the virtual paper trading platform.